Tag Archives: early stage

Hot Investor Mandate 2: Family Office with USA and UK Offices Seeks to Invest Up to $5M in Early-Stage Therapeutics Companies with Preference for Platform Technologies

24 May

A family office investment vehicle with offices in the USA and UK is looking to provide equity capital to USA-based therapeutic companies. The firm usually invests in Series A or B rounds, and will consider to participate in a seed round of financing. The firms typical deal size is variable, generally going as high as $5 million for an initial investment.

The firm is currently looking for companies developing Therapeutics. The firm is opportunistic in terms of sub-sector and indication though they do have a preference for companies with platform technologies. The firm is willing to invest in companies with a lead asset in preclinical through Phase II of clinical trials. The firm’s portfolio includes oncology, the microbiome, pain, neurological and rare diseases biotech companies.

The firm looks to invest in companies with experienced management teams. The firm is capable to act as either a lead or a co-lead investor and generally seeks board or board observer rights. As a pro-active investor, the firm will assist in the growth of a company, recruit new talents, develop preclinical, clinical and IP strategies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Company Acquired by Chinese Pharma Seeks Early to Mid-Stage Therapeutics Partnering Opportunities, Capable of Investing Up to $100M

17 May

A spin-out pharmaceutical company recently acquired by a Chinese pharmaceutical company is seeking early to mid-stage technology for equity, in-licensing, and acquisition opportunities, and typically invests $10M to $100M per project depending on the opportunity. In the past several years, the company also acquired two USA companies at $200-300M range. The company is seeking opportunities on a global level.

The firm is interested in early to mid-stage therapeutics in inflammatory diseases, cardiovascular diseases, diabetes, and cancer. The firm seeks preclinical to clinical stage pharmaceuticals with particular interest in large molecule biologics including naturally derived molecules and fermentation based products.

The firm is open to talking with companies, including virtual organizations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Chinese VC/PE Firm Works on Early and Late-Stage Deals in Medical Devices and Therapeutics with China Market Potential

17 May

A Shanghai-based venture capital/private equity firm manages both USD and RMB denominated funds. The firm invests in Series A rounds at $1-2M, though its sweet spot is investing $10-15M in Series B/C rounds. The firm works closely with local provincial Chinese governments, allowing them the ability to bring technology successfully into the Chinese market. The firm will generally not invest in the seed stage and seeks opportunities globally.

The firm invests in pharmaceuticals and Class II medical devices, including an interest in 505(b)(2) repurposed compounds, as well as healthcare-related industries. The firm is interested in all therapeutic areas and in early to mid-development stage companies. The firm focuses on unmet medical needs with a China market potential.

The firm does not have management team requirements. The firm will typically take a board seat post-investment, and has the capability to lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: San Francisco-based Large Global Private Investment Firm Seeking Early-Stage Therapeutics and Commercial-Stage Devices Worldwide

10 May

A large PE/VC is investing in life science innovation through its $5B Growth and Rise funds. The firm is a leading global private investment firm with over $59 billion AUM, based in San Francisco, California. The investment size typically ranges from $20M to $50M in equity. The firm is agnostic to company location or stage.

The firm aims to invest in therapeutics, commercial stage medical devices, and opportunistically in other innovative life sciences spaces. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III, and also commercial stage therapeutics. The firm is open to both PMA and 510K devices, as long as the device is already being sold at a commercial stage. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics.

The firm invests for the long term, and is heavily involved in, and committed to, the growth and success of their portfolio companies. The firm, therefore, generally take a board seat/observer rights. The firm only invests in private companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Japanese Pharma Launches New Global Initiative to Invest in Early-Stage Companies

26 Apr

A wholly-owned subsidiary of a global pharmaceutical company with headquarters in Japan is focused on developing innovative products in CNS, dermatology, and pain management. In particular, the pharma has established a strong global presence in transdermal patch products, and has several established products on the market.

The pharmaceutical company is seeking novel products for potential in-licensing and partnering opportunities to strengthen their current pipeline. In addition, the company is unveiling a new initiative through which the company will provide investment to early-stage technologies for which the company could help leverage clinical development. The size of investment will largely depend on the company’s stage of development, but the company is open to invest in seed to mid-stage companies. The company is seeking global opportunities.

With the new early-stage investment initiative, the company is interested in investing and partnering beyond the current focus areas: pain, CNS, and dermatology. Because of the company’s deep expertise in transdermal technology, the company can add significant values to companies with NCEs which can be delivered by patches. The company is also interested in reformulation and repositioning opportunities. The company will consider technologies as early as in development/pre-clinical.

The company has no specific management team requirements. The company has a development and regulatory team that can help companies with advancing towards FDA approval as well as Asian market entry, particularly Japan. Because the company has many resources and support to offer to early-stage companies, experienced management team and successful track record would be a plus, but not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Venture Arm of Global Medical Device Company Looking to Invest In or Partner with Early-Stage Companies Developing Platforms for Regenerative Medicine

26 Apr

A venture arm of a global medical device company that has worked with researchers and physicians for more than 50 years to develop more effective therapeutic tools, is focused on developing research and clinical tools to advance regenerative medicine therapies from the lab to the patient. The firm is focused on early-stage technologies and is flexible in terms of deal structures and partnerships with startup companies, including seed stage equity investments, strategic partnerships, and joint ventures/collaborations. The firm looks to be a dedicated partner working closely with startups to advance technologies and build companies. The firm has a global presence and is open to early-stage companies from around the world.

The firm’s core focus is on tools and bioprocessing platforms for regenerative medicine including, but not limited to, cell and gene therapies. Interests also include therapies that rely on immature or insufficient manufacturing tools and processes. Some examples of the firm’s products include a platelet lysate culture media to expand cell lines, automated fill/finish and thawing devices, a cryogenic vial to protect samples throughout lab processes, a blood filtration system for autologous cell therapy preparation and more.

The firm has no strict requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: VC Arm of Japanese Pharma Invests in Early-Stage Therapeutics and Platform Technologies in a Wide Range of Indications, Including CNS

19 Apr

A corporate venture subsidiary of a Japan pharmaceutical is looking to provide equity capital to seed and venture stage companies in the life science space, and invests across North America & Europe. The firm is looking to provide companies with $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year.

The firm is currently looking for companies developing Therapeutics and Platform Technologies. The firm is looking for companies in this sector working with small molecules, vaccines and biotherapeutics. Indications of interest include nephrology, cardiovascular, immunology, metabolic disease the firm is especially interested in companies working with therapies for CNS disorders such as ALS, inflammation, fibrosis, NASH and orphan indications. Ideal companies will have assets in preclinical stages of development.

The firm strongly prefers that the company has a strong management team with experience in the industry. The firm historically has only invested as a co-investor although they are capable and looking to take a lead position if the correct opportunity arises. The firm is looking to allocate to companies that will eventually be able to partner long term with its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: